Top news of the week: 26.07.2022.
Takeda Becomes Founding Sponsor of LabCentral to Help Life Sciences Startups Accelerate New Medical Treatments
/PRNewswire/ -- LabCentral today announced that Takeda, a global biopharmaceutical leader headquartered in Japan with a global U.S. hub located in...
‘Gold mine of unexplored biology’: Short protein sequences could dramatically expand human genome
New consortium will vet whether 7000-plus RNAs make stable proteins with cellular functions
Ginkgo to Acquire Zymergen
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's...
China-based biotech licenses Sanofi’s RNA drug technology
The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues.
State of CVC Q2’22 Report
Corporate venture capital firms pumped the brakes in Q2’22. Get all the figures and a ton of private market data in this report.
Vertex, Verve team up to develop a gene editing drug for liver disease
The deal, which is worth $60 million upfront, broadens Vertex’s reach into gene editing and expands Verve’s research beyond heart disease.
Jakob is 2 years old. He has a deadly disease. But drug companies won’t give him the cure — because they won’t make a big enough profit.
What's keeping kids with 'bubble boy' disease from living a normal life isn't their illness. It's the marketplace.
The life-sciences industry is a jewel in Britain’s economy
Policymakers can do more to help it sparkle